JUN-1111
Based on 1 Customer Validation
JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.57%
- No. CAS: 874351-38-9
- Fòrmula: C15H17N3O3
- Peso molecular:287.31
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
IC50:0.38 µM (Cdc25A); 1.8 µM (Cdc25B); 0.66 µM (Cdc25C); 28 µM (VHR); 37 µM (PTP1B)[1]
JUN-1111 (10, 30 µM; 17 h) induces cell cycle arrest at G1 and G2/M phase in tsFT210 cells[1].
JUN-1111 (10, 30 µM; 1 h) decreases the expression of phosphoCdk1 in a dose-dependent manner in tsFT210 cells[1].
JUN-1111 (0-20 µM) induces the formation of reactive oxygen species in mammalian cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:tsFT210 cells
-
Concentration:10, 30 µM
-
Incubation Time:17 h
-
Result:Induced cell cycle arrest at G1 and G2/M phases.
-
Cell Line:tsFT210 cells
-
Concentration:10, 30 µM
-
Incubation Time:1 h
-
Result:Decreased the expression of phosphoCdk1 in a dose-dependent manner.
Chemical Information
-
No. CAS 874351-38-9
-
Appearance Solid
-
Peso molecular 287.31
-
Fòrmula C15H17N3O3
-
Color Orange to reddish brown
-
SMILES
O=C(C=C1NCCN2CCOCC2)C3=C(N=CC=C3)C1=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 100 mg/mL (348.06 mM; ultrasonic and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.70 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.70 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Brisson M, et al. Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol. 2005 Dec;68(6):1810-20. [Content Brief]
[2]. Vogt A, et al. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther. 2008 Feb;7(2):330-40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4806 mL | 17.4028 mL | 34.8056 mL | 87.0140 mL |
| 5 mM | 0.6961 mL | 3.4806 mL | 6.9611 mL | 17.4028 mL | |
| 10 mM | 0.3481 mL | 1.7403 mL | 3.4806 mL | 8.7014 mL | |
| 15 mM | 0.2320 mL | 1.1602 mL | 2.3204 mL | 5.8009 mL | |
| 20 mM | 0.1740 mL | 0.8701 mL | 1.7403 mL | 4.3507 mL | |
| 25 mM | 0.1392 mL | 0.6961 mL | 1.3922 mL | 3.4806 mL | |
| 30 mM | 0.1160 mL | 0.5801 mL | 1.1602 mL | 2.9005 mL | |
| 40 mM | 0.0870 mL | 0.4351 mL | 0.8701 mL | 2.1754 mL | |
| 50 mM | 0.0696 mL | 0.3481 mL | 0.6961 mL | 1.7403 mL | |
| 60 mM | 0.0580 mL | 0.2900 mL | 0.5801 mL | 1.4502 mL | |
| 80 mM | 0.0435 mL | 0.2175 mL | 0.4351 mL | 1.0877 mL | |
| 100 mM | 0.0348 mL | 0.1740 mL | 0.3481 mL | 0.8701 mL |
JUN-1111 Related Classifications
HY-118529 Related Classifications
Powered by Bioz